The Synergistic Glucose-lowering Effects of Metformin and Bavachinin on Type II Diabetic Rats
Background: Diabetes is one of the most prevalent endocrine disorders in humans, and its first-line medication is metformin. Peroxisome proliferator-activated receptor gamma (PPAR–γ) agonists are the adjuncts to metformin. Bavachinin is a PPAR pan-agonist with fewer side effects than metformin"...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Arak University of Medical Sciences
2023-05-01
|
| Series: | Iranian Journal of Toxicology |
| Subjects: | |
| Online Access: | http://ijt.arakmu.ac.ir/article-1-1169-en.pdf |
| _version_ | 1797794483291553792 |
|---|---|
| author | Sara Khosraviani Ali Emami Samaneh Keshavarz Hedayati Sanaz Keshavarz Shahbaz Ehsan Aali Yazdan Naderi |
| author_facet | Sara Khosraviani Ali Emami Samaneh Keshavarz Hedayati Sanaz Keshavarz Shahbaz Ehsan Aali Yazdan Naderi |
| author_sort | Sara Khosraviani |
| collection | DOAJ |
| description | Background: Diabetes is one of the most prevalent endocrine disorders in humans, and its first-line medication is metformin. Peroxisome proliferator-activated receptor gamma (PPAR–γ) agonists are the adjuncts to metformin. Bavachinin is a PPAR pan-agonist with fewer side effects than metformin" into PPAR–γ agonists. In this study, the synergistic effects of metformin and Bavachinin were investigated on type II diabetic rats.
Methods: After four weeks of a high fat and glucose diet, type II diabetes was induced in 28 male Wistar rats, using injection of streptozotocin and nicotinamide. The animals were distributed into five groups of seven each: 1) Normal control (N), 2) Diabetic control (D), 3) Diabetic rats receiving metformin (DM), 4) Bavachinin (DB), and 5) Metformin plus Bavachinin (DMB). Oral glucose tolerance test (OGTT), fasting blood glucose (FBG), fasting insulin (FINS), homeostasis model assessment of β-cell function (HOMA-β), homeostasis model assessment of insulin resistance (HOMA-IR), and insulin sensitivity index (ISI) were obtained.
Results: The OGTT results in DM, DB, and DMB groups were significantly improved compared to that of D group. The FBG levels were significantly lower in DMB than in DB, DM, and D groups. The FINS levels of DMB were significantly less than those of DB, DM, and D groups. The HOMA-IR and HOMA-β were comparable between DMB and N groups. The ISI improved significantly in DMB compared to those in DM, DB, and D groups.
Conclusion: Bavachinin may be used combined with metformin for the treatment of type II diabetes at lower doses of metformin, thus having fewer side effects. |
| first_indexed | 2024-03-13T03:02:30Z |
| format | Article |
| id | doaj.art-45f7398471a64ba5afafdd9b332be4f2 |
| institution | Directory Open Access Journal |
| issn | 2008-2967 2251-9459 |
| language | English |
| last_indexed | 2024-03-13T03:02:30Z |
| publishDate | 2023-05-01 |
| publisher | Arak University of Medical Sciences |
| record_format | Article |
| series | Iranian Journal of Toxicology |
| spelling | doaj.art-45f7398471a64ba5afafdd9b332be4f22023-06-27T10:58:20ZengArak University of Medical SciencesIranian Journal of Toxicology2008-29672251-94592023-05-011727986The Synergistic Glucose-lowering Effects of Metformin and Bavachinin on Type II Diabetic RatsSara Khosraviani0Ali Emami1Samaneh Keshavarz Hedayati2Sanaz Keshavarz Shahbaz3Ehsan Aali4Yazdan Naderi5 Student Research Committee, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran. Student Research Committee, School of Medicine, Qazvin University of Medical Sciences, Qazvin, Iran. Department of Pharmacology, School of Medicine, Qazvin University of Medical Science, Qazvin, Iran. Cellular and Molecular Research Center, Research Institute for Prevention of Noncommunicable Disease, Qazvin University of Medical Sciences. Qazvin, Iran. Cellular and Molecular Research Center, Research Institute for Prevention of Noncommunicable Disease, Qazvin University of Medical Sciences. Qazvin, Iran. Cellular and Molecular Research Center, Research Institute for Prevention of Noncommunicable Disease, Qazvin University of Medical Sciences. Qazvin, Iran. Background: Diabetes is one of the most prevalent endocrine disorders in humans, and its first-line medication is metformin. Peroxisome proliferator-activated receptor gamma (PPAR–γ) agonists are the adjuncts to metformin. Bavachinin is a PPAR pan-agonist with fewer side effects than metformin" into PPAR–γ agonists. In this study, the synergistic effects of metformin and Bavachinin were investigated on type II diabetic rats. Methods: After four weeks of a high fat and glucose diet, type II diabetes was induced in 28 male Wistar rats, using injection of streptozotocin and nicotinamide. The animals were distributed into five groups of seven each: 1) Normal control (N), 2) Diabetic control (D), 3) Diabetic rats receiving metformin (DM), 4) Bavachinin (DB), and 5) Metformin plus Bavachinin (DMB). Oral glucose tolerance test (OGTT), fasting blood glucose (FBG), fasting insulin (FINS), homeostasis model assessment of β-cell function (HOMA-β), homeostasis model assessment of insulin resistance (HOMA-IR), and insulin sensitivity index (ISI) were obtained. Results: The OGTT results in DM, DB, and DMB groups were significantly improved compared to that of D group. The FBG levels were significantly lower in DMB than in DB, DM, and D groups. The FINS levels of DMB were significantly less than those of DB, DM, and D groups. The HOMA-IR and HOMA-β were comparable between DMB and N groups. The ISI improved significantly in DMB compared to those in DM, DB, and D groups. Conclusion: Bavachinin may be used combined with metformin for the treatment of type II diabetes at lower doses of metformin, thus having fewer side effects.http://ijt.arakmu.ac.ir/article-1-1169-en.pdfbavachinindiabetes mellitus type 2insulin resistancemetabolic syndromemetformin |
| spellingShingle | Sara Khosraviani Ali Emami Samaneh Keshavarz Hedayati Sanaz Keshavarz Shahbaz Ehsan Aali Yazdan Naderi The Synergistic Glucose-lowering Effects of Metformin and Bavachinin on Type II Diabetic Rats Iranian Journal of Toxicology bavachinin diabetes mellitus type 2 insulin resistance metabolic syndrome metformin |
| title | The Synergistic Glucose-lowering Effects of Metformin and Bavachinin on Type II Diabetic Rats |
| title_full | The Synergistic Glucose-lowering Effects of Metformin and Bavachinin on Type II Diabetic Rats |
| title_fullStr | The Synergistic Glucose-lowering Effects of Metformin and Bavachinin on Type II Diabetic Rats |
| title_full_unstemmed | The Synergistic Glucose-lowering Effects of Metformin and Bavachinin on Type II Diabetic Rats |
| title_short | The Synergistic Glucose-lowering Effects of Metformin and Bavachinin on Type II Diabetic Rats |
| title_sort | synergistic glucose lowering effects of metformin and bavachinin on type ii diabetic rats |
| topic | bavachinin diabetes mellitus type 2 insulin resistance metabolic syndrome metformin |
| url | http://ijt.arakmu.ac.ir/article-1-1169-en.pdf |
| work_keys_str_mv | AT sarakhosraviani thesynergisticglucoseloweringeffectsofmetforminandbavachininontypeiidiabeticrats AT aliemami thesynergisticglucoseloweringeffectsofmetforminandbavachininontypeiidiabeticrats AT samanehkeshavarzhedayati thesynergisticglucoseloweringeffectsofmetforminandbavachininontypeiidiabeticrats AT sanazkeshavarzshahbaz thesynergisticglucoseloweringeffectsofmetforminandbavachininontypeiidiabeticrats AT ehsanaali thesynergisticglucoseloweringeffectsofmetforminandbavachininontypeiidiabeticrats AT yazdannaderi thesynergisticglucoseloweringeffectsofmetforminandbavachininontypeiidiabeticrats AT sarakhosraviani synergisticglucoseloweringeffectsofmetforminandbavachininontypeiidiabeticrats AT aliemami synergisticglucoseloweringeffectsofmetforminandbavachininontypeiidiabeticrats AT samanehkeshavarzhedayati synergisticglucoseloweringeffectsofmetforminandbavachininontypeiidiabeticrats AT sanazkeshavarzshahbaz synergisticglucoseloweringeffectsofmetforminandbavachininontypeiidiabeticrats AT ehsanaali synergisticglucoseloweringeffectsofmetforminandbavachininontypeiidiabeticrats AT yazdannaderi synergisticglucoseloweringeffectsofmetforminandbavachininontypeiidiabeticrats |